Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,056,984
  • Shares Outstanding, K 105,099
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,688 M
  • EBITDA $ 4,171 M
  • 60-Month Beta 0.37
  • Price/Sales 5.49
  • Price/Cash Flow 16.24
  • Price/Book 2.52

Options Overview Details

View History
  • Implied Volatility 26.91% (-2.32%)
  • Historical Volatility 43.84%
  • IV Percentile 1%
  • IV Rank 2.06%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 8) 0.00 (0.00%)
  • Put/Call Vol Ratio 2.20
  • Today's Volume 2,872
  • Volume Avg (30-Day) 2,432
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 57,142
  • Open Int (30-Day) 55,726
  • Expected Range 722.80 to 722.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 8.24
  • Number of Estimates 6
  • High Estimate 10.82
  • Low Estimate 6.92
  • Prior Year 9.90
  • Growth Rate Est. (year over year) -16.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
628.00 +15.10%
on 11/05/25
790.98 -8.62%
on 11/26/25
+94.80 (+15.10%)
since 11/04/25
3-Month
541.00 +33.60%
on 10/13/25
790.98 -8.62%
on 11/26/25
+155.58 (+27.43%)
since 09/04/25
52-Week
476.49 +51.69%
on 06/05/25
800.99 -9.76%
on 12/09/24
-31.46 (-4.17%)
since 12/04/24

Most Recent Stories

More News
3 Cash-Producing Stocks We Find Risky

3 Cash-Producing Stocks We Find Risky

HLMN : 8.99 (-1.43%)
OGN : 7.14 (-1.79%)
REGN : 722.80 (-0.12%)
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

NVDA : 183.38 (+2.11%)
XLV : 153.90 (-0.76%)
JNJ : 202.48 (-1.39%)
LLY : 1,014.49 (-1.85%)
IBB : 172.11 (-0.07%)
GILD : 122.62 (-1.90%)
REGN : 722.80 (-0.12%)
AMGN : 340.16 (-1.52%)
UNH : 333.49 (-1.83%)
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million,...

REGN : 722.80 (-0.12%)
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?

Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

$SPX : 6,857.12 (+0.11%)
INCY : 100.46 (-1.02%)
REGN : 722.80 (-0.12%)
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...

SAN.FP : 84.570 (-1.25%)
REGN : 722.80 (-0.12%)
SNY : 48.90 (-1.59%)
These 3 Stocks Gained When Seemingly Everything Else Sold Off Last Week. Are They Worth a Buy Here?

Nvidia drove a tech stocks rout, but these three “boring” names are showing signs of a turnaround.

MKC : 63.44 (-1.06%)
EIX : 57.55 (+0.44%)
$SPX : 6,857.12 (+0.11%)
REGN : 722.80 (-0.12%)
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

A : 148.32 (-0.63%)
MRK : 100.89 (-1.35%)
WAT : 396.37 (-0.31%)
MTD : 1,422.81 (-0.84%)
REGN : 722.80 (-0.12%)
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

$SPX : 6,857.12 (+0.11%)
IBB : 172.11 (-0.07%)
REGN : 722.80 (-0.12%)
3 Nasdaq 100 Stocks We Keep Off Our Radar

3 Nasdaq 100 Stocks We Keep Off Our Radar

PCAR : 108.50 (-0.04%)
MCHP : 64.72 (+1.75%)
REGN : 722.80 (-0.12%)
Stocks Reverse Sharply Lower as Tech Stocks Get Crushed

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down by -1.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.84%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -2.38%....

MSTR : 186.01 (-1.26%)
SOLV : 85.26 (+0.01%)
GOOGL : 317.62 (-0.63%)
AMAT : 269.44 (+0.30%)
AAPL : 280.70 (-1.21%)
NDAQ : 90.29 (+2.23%)
PACS : 31.49 (+0.48%)
GLXY : 27.57 (+1.92%)
DDOG : 153.00 (-1.82%)
J : 140.73 (+1.44%)
$IUXX : 25,581.70 (-0.10%)
BBWI : 19.01 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 745.24
2nd Resistance Point 740.12
1st Resistance Point 731.46
Last Price 722.80
1st Support Level 717.68
2nd Support Level 712.56
3rd Support Level 703.90

See More

52-Week High 800.99
Last Price 722.80
Fibonacci 61.8% 677.03
Fibonacci 50% 638.74
Fibonacci 38.2% 600.45
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar